Filter your search
Kalorama Information is a dependable resource for information on opportunity in the pharmaceutical market. The pharma industry has seen important developments in the last few years, bringing both challenges and new opportunities. The industry outlook for many manufacturers has changed due to outsourcing in drug discovery, growing generic competition and greater interest in biotechnology, among other developments. Our reports provide the sales data, revenue forecasts, and competitive analysis that one needs to understand the market.
Manufacturing & Packaging
- The OTC women’s health market encompasses a wide variety of products that have been determined safe and effective as over-the-counter products. The market is driven by several factors including increasing number of baby boomers entering old age, increasing incidences of diseases; product demand; and several others. In response to many inquiries from readers of Kalorama […]August 1, 2003Drug delivery technologies continue to be a vital piece of the pharmaceutical marketing puzzle. From clinical efficacy to product differentiation and life-cycle management, delivery technologies are increasingly demanding the attention of developers at earlier and earlier stages. In Kalorama’s 2001-2002 Drug Delivery series, we focused on the markets by route of administration—oral, injectable, implantable, pulmonary, […]July 18, 2003$2,062 – $4,152The number and scope of drug discovery outsourcing agreements has grown rapidly over the past five years, and the pace will accelerate over the next five years. Outsourcing is now an essential part of drug discovery. Major pharmas and biotechs are aggressively pursuing a range of outsourcing agreements. On the supplier side, smaller vendors rely […]May 1, 2003$2,625 – $5,250Switching dosages and ingredients of prescription medicines to the over-the-counter market is not new. In the past 30 years, more than 70 switches have produced hundreds of brands competing in the consumer market, and the pace promises to accelerate. Going OTC is one of a number of strategies marketers can use to extend the revenue […]May 1, 2003$1,875 – $3,750This report analyzes the world markets for human antiviral medications, focusing on the current market for and the development of drugs that are used to directly combat and treat viruses viral infections. For the purposes of this report, antivirals are drugs used to directly treat viral infection after it occurs. The report does not discuss […]April 1, 2003World Market for Anti-infectives Series: Volumes I - III - Antifungals, Antibacterials and Antivirals, The$6,000 – $12,000Once a public health problem pegged for easy elimination, infectious diseases continue to be the leading cause of death worldwide. Despite improved methods of treating and preventing infection, including potent antibiotics, comprehensive immunization, and modern sanitation, infection still accounts for much serious illness, even in highly industrialized countries. Use this new Kalorama Information 3-volume series […]April 1, 2003$1,875 – $3,750Each year in the United States, more than 500,000 people with coronary artery disease are treated with percutaneous transluminal coronary angioplasty (PTCA). Unfortunately, restenosis occurs within three to six months in 40% to 50% of PTCA patients due to either thrombosis or abnormal tissue growth. As a result, restenosis constitutes the major limitation to the […]April 1, 2003During the last 25 years, there have been unprecedented advancements in the area of women’s health and there is widespread recognition of the importance of addressing conditions that overwhelmingly affect women. Likewise, pharmaceutical marketers have increasingly understood the potential that the women’s health market represents and the increasing clout female consumers are wielding in the […]March 1, 2003$2,500 – $5,000Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the […]January 1, 2003In the summer of 2002, Kalorama Information released a major study on non-psychiatric neurotherapeutic drug markets. At almost 500 pages, the resulting report covered a broad range of neurological agents comprehensively and in depth; however, the breadth and authority of the results proved to be more information than some marketers needed. Smaller biopharmaceutical concerns—some of […]January 1, 2003